Introduction

The antibacterial sector is highly saturated, demonstrating only limited growth. Consequently, key players are now channeling their resources away from this field into other areas, resulting in a relatively limited pipeline. However, there remain a number of promising products in late-stage development, which may have a significant impact on current market dynamics. 

Scope

Overview of antibacterial product development, detailing major antibacterial classes, as well as current clinical trial methodology  

Sales forecasts based on drug profiles, historical trends and discussions with key opinion leader input 

Report Highlights

The antibacterials sector, currently valued at around $27 billion, will remain flat with little growth forecast to 2011. Market saturation, product restriction and the short acute nature of therapy are reducing the incentive for pharmaceutical companies to invest in this area. 

Reasons to Purchase

Identify pipeline compounds that may impact on the performance of current market leaders 

Benchmark in-house forecasts against Datamonitor’s predictions for future sales of pipeline antibacterials 

Scope

Description and analysis of antibacterials in late-stage development, highlighting how they fulfill unmet needs in this sector 

Sales forecasts based on drug profiles, historical trends and discussions key opinion leader input 

Report Highlights

Datamonitor reveals that there is a marked difference in the number of products in the antibacterial pipeline for each respective class. For some groups, such as the penicillins and tetracyclines, there is minimal activity. 

Entirely new compounds need clear product distinction to gain advantage in the antibacterial market. A good example is Ramoplanin, a developmental oral glycopeptide intended to VRE blood-stream infections. Antibacterial prophylaxis, inhalable formulations and oral equivalents may introduce various paradigm shifts in current therapeutic practices. 

Reasons to Purchase

Identify pipeline compounds that may impact on the performance of current market leaders. 

December 2003, 275 pages 

Publisher: Datamonitor Infectious Diseases Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Infectious_Diseases.html#a34